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Introduction 
Sulphasalazine has been widely used for the treat- 
ment of inflammatory bowel disease for almost 50 yr 
and in the last decade has been increasingly used for the 
treatment of rheumatological conditions. It is a combi- 
nation of 5-aminosalicylic acid (ASA) and sulpha- 
pyridine linked by a diazo bond. Adverse reactions are 
many, common and lead to discontinuation of therapy 
in 20-30% of patients. More serious side effects such 
as leukopenia, haemolytic anaemia and deranged 
hepatic function are less common while drug-induced 
pulmonopathy is rare (1). Pulmonary complications 
may be confused with manifestations of the underlying 
disease while the management and prognosis may be 
very different. 
We report a patient who developed an unusual form 
of drug-induced pulmonopathy 17 months after start- 
ing sulphasalazine for a rheumatological condition not 
associated with pulmonary complications. 
Case Report 
A 67-year-old woman complained of recurrent 
arthritis in her first meta-tarsophalangeal joints for 
20 yr before commencing allopurinol for presumed 
gout in 1975. In 1987 she developed pain and swelling 
of both wrists and several distal interphalangeal joints. 
Radiographs showed chondrocalcinosis in both wrists 
and knees consistent with calcium pyrophosphate 
deposition disease. Allopurinol was stopped and she 
was commenced on diclofenac sodium. In July 1988, 
because of persistent joint pain and scaling of the 
elbows and scalp, a presumptive diagnosis of psoriatic 
arthritis was made. Tests for rheumatoid factor and 
antinuclear antibodies were negative. Enteric-coated 
sulphasalazine was begun at a dose of 0.5 g daily, 
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progressing to 1.0 g twice daily, which produced 
considerable improvement in joint symptoms. Two 
dermatologists subsequently felt that the diagnosis was 
asteatotic eczema rather than psoriasis. In November 
1989 she developed paroxysmal non-productive cough 
and dyspnoea on mild exertion. 
Hypertension had been well controlled on cyclo- 
penthiazide 0.5 mg daily and pindolol 15 mg twice a 
day for 15 yr and these drugs were continued. She 
had a 35 pack per year smoking history but had not 
smoked for 20 yr. She had no exposure to dusts, fumes, 
chemicals or specific organic antigens. There was no 
previous history of drug allergy. 
On examination she was afebrile and on auscultation 
medium inspiratory bilateral basal crackles to the mid- 
chest were heard. There was no finger clubbing, 
lymph-adenopathy, hepatosplenomegaly nor ocular 
abnormality. 
Investigations showed a haemoglobin of 122glF’ 
white blood count 8.5 x lo9 I-’ with 86% neutrophils, 
9% lymphocytes, no eosinophils and an ESR of 
39 mm h-l. Electrolytes, liver function tests, uric acid 
and thyroid function tests were all normal. Arterial 
blood gas on air results were pH =7.49, PCO,= 
34 mmHg (4.5 kPa), PO,= 70 mmHg (9.3 kPa), bicar- 
bonate=26 mmol 1-l and an oxygen saturation of 
95%. Chest radiograph [Plate l(a)] revealed bilateral 
basal alveolar and interstitial opacities. Serum precipi- 
tins, rheumatoid factor, tissue auto-antibodies and 
viral and chlamydia antibody titres were all negative. 
Pulmonary function tests showed a restrictive pattern, 
impaired CO transfer and desaturation on exercise. 
Bronchoscopy revealed a normal tracheobronchial 
tree. Histology of transbronchial lung biopsies showed 
a range of changes, predominently in the alveolar 
walls. The majority of alveolar walls were normal. 
Some were thickened by mature fibrous tissue and 
some contained an infiltrate of histiocytes and lym- 
phocytes. In areas, these histiocytes had an epithelioid 
appearance and multinucleated giant cells were seen. 
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Pla fe I Serial chest radiographs. (a) At presentation, (b) 5 months after presentation showing complete I 
bila .teral, predominantly basal and peripheral, pulmonary parenchymal shadowing. 
.esolution of the 
Isolated Masson bodies were present. The appear- Sulphasalazine was stopped and because of a lack 
antes were those of sub-acute hyper-sensitivity of improvement over days she was commenced on 
pneumonitis (Plate 2). prednisone 30 mg daily. Serial chest radiographs and 
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Plare 2 Histology of transbronchial biopsy. The alveolar wall is thickened by an infiltrate of lymphocytes and histiocytes with 
formation of giant cells and a loose granuloma. 
pulmonary lung function tests showed improvement 
over the following months. She returned symptomati- 
cally, radiologically [Plate l(b)] and physiologically to 
normal after 6 months. Prednisone was gradually dis- 
continued over a total of 6 months. At more than a 
year after steroid cessation there has been no further 
deterioration in symptoms or pulmonary function. 
Re-challenge was not undertaken. 
Discussion 
Pulmonary complications of sulphasalazine therapy 
are rare. Most reported cases of drug-induced pul- 
monopathy due to sulphasalazine in which pulmonary 
histology was available may be classified as an eosino- 
philic pneumonitis (2-10). Diffuse interstitial fibrosis 
(fibrosingalveolitis) (11-l 5) and obliterative bronchio- 
litis have also been reported (6,8). This is the first 
report of sub-acute hyper-sensitivity pneumonitis in 
association with sulphasalazine. Raforth (16) reported 
the case of a young woman who developed systemic 
non-caseating granulomata 3 weeks after starting 
sulphasalazine for Crohn’s disease. However, non- 
caseating granulomata are well recognized in non- 
digestive tissue in Crohn’s disease, reflecting its 
multi-system nature. Occasional granulomata were 
noted in the case reported by Williams et al. (6), 
although the major histological abnormalities were of 
bronchiolotis obliterdns and fibrosing alveolitis. 
Most cases of sulphasalazine-induced pulmonopathy 
have been reported in patients receiving the drug for 
inflammatory bowel disease. In the English literature 
there are only two other cases of sulphasalazine- 
induced lung disease reported in patients taking the 
drug for other than inflammatory bowel disease 
(17,18). Both patients had rheumatoid arthritis. No 
pulmonary histology was presented in one, whilst in 
the other the pattern was that of fibrosing alveolitis - 
also, the type of diffuse interstitial lung disease associ- 
ated with rheumatoid disease. The development of 
bilateral pleural effusions in the case reported by 
Geborek et al. (17) would be most unusual for drug- 
induced pulmonopathy and thus raises the possibility 
that both the effusions and lung parenchymal disease 
were complications of the rheumatoid arthritis. 
Despite the temporal relationship with sulphasalazine 
administration, the case described by Boyd et al. (18) 
may represent ‘rheumatoid lung’ responding to oral 
corticosteroids. 
The patient described in this report had a rheumato- 
logical condition not associated with pulmonary 
complications. Whilst a definite aetiologic role for 
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sulphasalazine cannot be proven in the absence of re- 
challenge, it is likely that sulphasalazine was the 
etiologic agent in this case because of the temporal 
relationship between drug introduction and the devel- 
opment of symptoms, the lack of other medical con- 
ditions or exposures which may have been responsible 
for interstitial lung disease and the lack of recurrence 
ofdiseasefollowing withdrawal oforal corticosteroids. 
This patient did not improve following cessation of 
the drug and oral cortico-steroids were required for 
symptomatic improvement and for restoration of 
pulmonary function to normal. This feature is well 
recognized in other drug-induced pulmonopathies, 
particularly those forms other than acute eosinophilic 
pneumonitis (19). Perhaps once the immunological 
mechanism is underway, drug withdrawal alone is 
insufficient to reverse it. 
Which component of the drug and the mechanism of 
action responsible for the type of pulmonopathy seen 
in this case are unknown. In cases of sulphasalazine- 
induced alveolitis, the sulphapyridine component has 
been thought responsible because when this moiety 
was replaced re-challenge occurred without adverse 
effect. Also, eosinophilic pneumonitis has been 
reported in association with sulphonamide use (20). 
Aspirin has been implicated as the causative agent in 
eosinophilic pneumonitis (21) and non-cardiogenic 
pulmonary oedema (22). It is uncertain as to whether 
these complications may also be associated with 5- 
amino-salicylic acid. The type of inflammation in this 
present case suggests a type of delayed hyper-sensitivity 
reaction to a component of the drug. Non-caseating 
granulomata in the liver and lymph nodes have been 
reported in association with drug hypersensitivity, 
including to the sulphonamides (23). 
Hence, sulphasalazine must be considered as a 
potential cause of diffuse lung disease in patients 
taking the drug for rheumatological conditions as well 
as inflammatory bowel disease. This case illustrates 
that sulphasalazine may be associated with sub-acute 
hypersensitivity pneumonitis, as well as previously 
recognized forms of drug-induced lung disease. 
Clinical, radiological or physiological features cannot 
reliably distinguish the various histological forms of 
sulphasalazine-induced pulmonopathy and a definitive 
histological diagnosis is essential. 
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